Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen.
OBJECTIVE
Benign prostatic hyperplasia (BPH) is among the most common diseases affecting quality of life in older men. Despise intense research efforts to our knowledge the genetic mechanisms underlying the BPH disease process and therapeutic markers needed to determine patient responsiveness to a particular form of pharmacological therapy are still not identified. This has slowed the development of new therapeutic agents for the treatment of BPH.


METHODS
We investigated the cellular effects of certain drugs on BPH. Besides doxazosin, which is the prevailing drug to treat BPH, the effect of ibuprofen was examined as a new therapeutic approach due to strong evidence of a correlation between BPH and inflammation.


RESULTS
This study showed that doxazosin as well as ibuprofen significantly decreases cell viability and induced apoptosis in 267 B1 cells as well as in BPH-1 cells. In addition, we observed that the administration of doxazosin and ibuprofen to BPH-1 cells decreased the expression of JM-27, a protein particularly expressed in prostate that is highly up-regulated in symptomatic BPH.


CONCLUSIONS
Our findings suggest that ibuprofen may be a new therapeutic target for the treatment of BPH. Further research must be done to investigate the potential use of ibuprofen in patients with BPH and examine if JM-27 expression in patients with BPH may stratify individuals who may be most responsive to pharmacological treatment.
Minnery
Cynthia H
CH
Department of Urology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
Getzenberg
Robert H
RH
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000951:Antigens, Neoplasm; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D017292:Doxazosin / Q000494:pharmacology*; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology*; D008297:Male; D011470:Prostatic Hyperplasia / Q000473:pathology*; D011506:Proteins / Q000187:drug effects* / Q000502:physiology*
D000317:Adrenergic alpha-Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000951:Antigens, Neoplasm; C474505:PAGE4 protein, human; D011506:Proteins; D017292:Doxazosin; D007052:Ibuprofen